A bill passed by the state legislature in March then signed into law by Democratic Gov. Jared Polis allows Colorado to further uncouple itself from federal guidance.

The law allows health officials to follow the recommendations of national medical groups when making decisions such as purchasing bulk vaccines for the Medicaid program.

“We are insulating our state from the dysfunction coming out of Washington,” said Democratic state Sen. Kyle Mullica, a co-sponsor of the bill and a registered nurse. “We’re going to rely on science.”

“From fighting during the pandemic for Coloradans to get vaccines as quickly as possible to combating the Trump Administration’s barriers to getting vaccinated, we have expanded access to vaccines for Coloradans who want them,” Polis said in a statement when he signed the law.

Colorado is one of at least 29 states that, along with Washington, D.C., have taken steps to bypass the new federal recommendations amid worries that the changes could chip away at public trust in vaccines and erode broad vaccine coverage.

Previously, Colorado, like most states, had followed federal guidance set by the Centers for Disease Control and Prevention. In January, CDC advisory panelists, selected by Health and Human Services Secretary Robert F. Kennedy Jr., removed six pediatric immunizations from the agency’s universal recommendation list.

Last year, doctors, scientists, local leaders, and other supporters came together to form an outreach and advocacy coalition called Colorado Chooses Vaccines.

The group aims to offer a clear, unified voice on the proven benefits of vaccines and reassure residents confused by the many federal changes.

Carol Boigon, a former Denver City Council member, joined the group because she wants more people to hear her own chilling story about vaccine-preventable illness.

“Every summer everybody got sick,” Boigon said, recounting her childhood in 1950s Detroit.

The illness was polio, a highly contagious viral disease that attacks the nervous system, sometimes causing partial or full paralysis.

During the summer of 1953, “the whole block was sick and some of us got crippled, and that was just the way it was,” she said.

New Group Steps Up

Boigon’s personal history will be part of the coalition’s work to educate new generations about the dangers of infectious diseases that were once common in the U.S. but are now relatively rare.

The group, which formed last September, will also compile vaccine information from medical groups and the state health department and advocate for policy proposals with the state government.

“It was in direct response to the federal threats,” said another coalition member, former state lawmaker Susan Lontine. She leads the nonprofit Immunize Colorado.

Another member, public relations specialist Elizabet Garcia, wants more outreach to Hispanics, whose vaccination rates lag behind other groups’.

“A lot of time it’s this fear that they’re going to have to pay out-of-pocket, that their insurance doesn’t cover it, that they might not even have insurance in general,” Garcia said.

Boigon was 5 when she got sick and was hospitalized for six weeks with a fever. The virus attacked her spine.

“None of my limbs worked immediately afterwards,” Boigon said.

Although she regained function in her other limbs, her right arm never fully recovered. She had to adapt, relearning everyday tasks such as reaching out to shake hands with people with her left hand.

In 1955, not long after she got sick, the new polio vaccine became more widely available to the public. As vaccinations took off, U.S. cases of polio, once one of the nation’s most feared diseases, dropped by an estimated 85%-90%.

Increasing Public Trust

State leaders have taken other steps to promote public health. After the Trump administration pulled the U.S. out of the World Health Organization, several states, including Colorado, decided to join the WHO’s Global Outbreak Alert and Response Network on their own.

Colorado also joined a multistate lawsuit challenging the Trump administration’s changes to the childhood vaccine schedule.

And the new state law has provisions besides allowing the state to diverge from federal recommendations. It codifies pharmacists’ ability to prescribe and give vaccines themselves. It also increases legal protections for healthcare workers who give vaccines.

“This law will provide more clarity to guide all Coloradans, including providers who administer vaccines,” Lontine said.

But the legislation has opponents who say it would interfere with parental choice and claim vaccines might be unsafe or ineffective.

“I just want to make sure we’re not just getting into a big political dispute between the federal recommendations — the CDC and so forth — and different political views in Colorado here,” said Republican state Sen. John Carson, who voted against the vaccine bill.

NPR contacted the U.S. Department of Health and Human Services about Colorado’s new law. Spokesperson Emily Hilliard answered in an email: “The updated CDC childhood schedule continues to protect children against serious diseases.”

Preventable Illnesses Surge

The flurry of statewide activity comes as Colorado and the nation have seen surges in illnesses such as flu and measles.

As of mid-May, Colorado had recorded 22 measles cases this year. In 2025, it registered 36 cases, according to the state health department, far surpassing totals from previous years.

Across Colorado, kindergarten vaccination rates for measles were 88% last school year — with only a few counties achieving rates of 95%, the level needed for herd immunity, according to data published by The Washington Post in December.

This has also been Colorado’s worst flu season in recent years.

Vaccination rates for both flu and covid-19 have dropped slightly in Colorado, according to the state health department.

Eight children in Colorado have died this season from flu; one from covid; and one from RSV, or respiratory syncytial virus. Vaccines for all three are available for children and recommended by the state’s health department.

Kennedy, a longtime anti-vaccine activist, has defended his decisions to overhaul the recommended schedule for childhood vaccinations.

In March, a federal judge put on hold many of the changes.

“We’re not taking vaccines away from anybody. If you want to get the vaccine, you could get it. It’s going to be fully covered by insurance just like it was before,” Kennedy told CBS News in January.

When a reporter suggested the new changes could result in fewer people getting a flu vaccine, Kennedy said: “Well, that may be, and maybe that’s a better thing.”

Boigon is sometimes incredulous at everything that has happened.

“It’s like we’re going backwards,” she said. “It’s like we have decided we don’t want a modern life; we want to be back in the 1950s, where children are sick and dying.”

This article is from a partnership with Colorado Public Radio and NPR.

The post Colorado Charts Its Own Course on Vaccines Amid Federal Pullback appeared first on Medika Life.

Despite this extraordinary pace of innovation, something fundamental remains broken. Patients still struggle to navigate care. Physicians continue to wrestle with fragmented systems, administrative overload and technologies that often add work rather than reduce it. Health innovators repeatedly introduce sophisticated tools into environments overwhelmed by operational complexity, lack of governance, cybersecurity concerns, workflow disruption and communication gaps.

The issue is no longer whether innovation benefits care. The issue is friction.

Consumers compare health care experiences to every interaction in daily life. They compare health care to Apple, where design simplifies complexity, to Amazon, where communication is continuous and immediate, and to banking and travel platforms providing real-time updates and seamless transactions. Some may even compare it to Domino’s Pizza, which promises delivery within 15 minutes or the pie is free. Expectations surrounding responsiveness and convenience have fundamentally changed.

Then they enter health care environments where forms are repeated, portals fail to communicate, prior authorizations delay treatment and updates disappear into silence. Patients are left to navigate disconnected systems during moments of vulnerability. The expectation gap between consumer and health care experiences continues to widen and increasingly shapes reputation.

In Healing the Sick Care System: Why People Matter, the observation is made that “Health care isn’t failing because we lack innovation. It’s failing because the system around that innovation has calcified.” The statement remains painfully real because innovation alone does not create confidence. Experience does.

Patients Remember the Journey, Not the Molecule

The patient and physician experience is shaped less by what a product promises and more by what happens after that promise enters real life. A medicine may be clinically meaningful, yet the experience surrounding it can still become exhausting if coverage is difficult to secure, prior authorization is confounding, specialty pharmacy coordination is slow, follow-up instructions are unclear or support programs require patients to become navigators of their own care.

In those moments, people are not judging science on its own merits. They are judging the total experience of trying to make that medicine or care available and understandable.

Physicians face their own administrative version of friction. A therapy may be medically appropriate, yet before treatment can begin, office staff must determine coverage, complete documentation, respond to payer step-through requirements, manage rejection appeals and explain delays that were never created in the exam room. Every additional administrative step consumes time, stretches staff and places additional strain on the physician-patient relationship. Even non-medical formulary changes can force physicians to restart conversations, explain unexpected medication switches and reestablish patient confidence in treatment decisions already made.

Patients remember counting the hours as they waited for answers. Physicians remember losing uncompensated time navigating systems and approvals. Nurses remember caring for patients through computer screens while typing notes into laptops on rolling carts in crowded hallways. Office managers remember the relentless cycle of paperwork, rejected claims, disconnected portals and endless callbacks trying to move care forward.

The therapy may eventually do its job, yet the pathway becomes inseparable from the memory associated with the brand, the company and the broader health care system. Every new process, technology and treatment promises improvement. For patients and health professionals, however, if the path to care feels uphill, the friction surrounding the experience can overshadow the value of the benefit.

For many patients, repeated uncertainty, delays and administrative obstacles contribute to a form of medical PTSD, where anxiety surrounding the system becomes inseparable from the treatment experience. For health professionals, the constant burden of navigating fragmented systems, managing approvals and compensating for communication gaps has become a leading contributor to burnout.

Friction is rarely remembered as an operational issue inside organizations. Patients and physicians experience it personally. This is why communication must be elevated operationally within health care. Communication is not marketing layered onto innovation after development is complete.

Health care organizations often think they are going through the process of delivering a product, therapy or platform. Patients and physicians experience something more personal: time invested in every interaction surrounding the innovation is time lost forever.

Health Technology Cannot Create More Work

The same reality applies to health technology startups and digital health innovators. Technological advancement alone does not guarantee adoption within health care environments already burdened by operational complexity and workforce fatigue.

Health care organizations do not merely evaluate whether technology works. They evaluate whether it integrates with existing workflows, whether cybersecurity standards are state-of-the-art, whether onboarding is manageable, whether interoperability gaps create additional burdens, and whether the institution can trust the accuracy of data.

Every additional step is a friction point, while every unresolved operational issue becomes part of the patient and physician experience surrounding the journey.

A sophisticated AI platform that requires clinicians to validate outputs continuously adds cognitive burden. A monitoring platform generating clinically important alerts contributes to fatigue. A system that requires extensive retraining or manual workarounds may succeed in demonstration but stumble in real-world conditions.

Innovation may arrive elegantly designed; however, it enters health care environments already strained by workflow complexity, disconnected systems, cybersecurity demands and administrative fatigue. The operational realities surrounding implementation often become as important as the innovation itself.

That reality does not diminish the importance of continuous invention. It reinforces the importance of implementation, communication and operational design within real-world clinical environments.

This shift is increasingly visible across the global health innovation marketplace itself. At HLTH Europe 2026, conversations are moving well beyond excitement surrounding artificial intelligence, digital therapeutics and next-generation platforms. The agenda sessions focus on interoperability, workflow integration, governance, patient engagement and operational implementation. Conference themes repeatedly emphasize connected systems, coordinated experiences and technologies that reduce fragmentation rather than add to a growing list of patches.

One of the more revealing themes from HLTH Europe focuses directly on interoperability and the longstanding frustration surrounding disconnected systems. The conference site notes that clinicians continue spending enormous energy managing platforms that fail to communicate effectively with one another. At the same time, artificial intelligence is increasingly viewed not as a replacement for care, but as a bridge helping systems “finally speak the same language.”

Another major focus involves provider realities. HLTH Europe speakers highlight workforce fatigue, cyber risks, operational strain and workflow challenges facing clinicians and health systems across Europe and beyond. These agenda themes reinforce a growing recognition throughout the industry that innovation cannot succeed if it increases the burden for the people expected to use it every day.

Health professionals increasingly describe a workplace dominated by more screens, more alerts, more documentation and less time with patients. Technology interrupting workflow rather than integrating into it creates resistance, regardless of how advanced the platform may appear. The hidden work behind implementation often becomes the defining experience for the people expected to use the system every day.

Cybersecurity provides another important example. Health professionals and patients may never fully understand the technical architecture protecting health information, yet they absolutely understand the emotional consequence of uncertainty surrounding data privacy, reliability and trust. Confidence in health technology is not built solely through functionality. It is reinforced through consistency, service, transparency and confidence that information is accurate, protected and responsibly governed.

Communication plays an equally important role here. If clinicians are left uncertain about updates, system changes or data governance responsibilities, confidence weakens. If patients do not understand how information is protected, trust erodes, regardless of how advanced the technology.

Communication remains inseparable from the care experience.

The organizations most likely to lead the future of health care will not distinguish themselves solely through technological achievement. They will reduce friction around the user interface, workflows and data accuracy.

The Companies That Win Will Simplify Complexity

This reality explains why access organizations such as Hims & Hers Health and Cost Plus Drugs deserve careful study from across the health care sector, regardless of whether industry leaders agree with every aspect of their business models. These organizations are built around reducing friction in how people access and experience care.

Their importance extends beyond convenience or pricing. These companies recognize that many traditional health institutions have underestimated: people increasingly expect health care experiences to reduce anxiety, simplify decision-making and provide continuity throughout the care journey.  They are “Amazon-like,” offering a “Buy It Now” simple click medical oversight option.

The rise of concierge medicine, direct-to-consumer health platforms and walk-in clinics with reduced wait times reflects a broader market signal the health sector cannot ignore. Patients are increasingly gravitating toward experiences where communication is clearer and access is more immediate.

For those able to afford concierge care, the attraction often extends beyond physician access itself. Patients value responsiveness, shorter wait times, easier scheduling, follow-up communication and the sense that someone is helping coordinate their journey through the system. Walk-in clinics and urgent care centers appeal for similar reasons. People are searching for environments where care is readily accessible, understandable and administratively manageable. The downside of loss of care continuity is offset by immediacy, which is what the consumer values most.

This migration reflects frustration with friction embedded throughout the trending health care experience. Long hold times, delayed callbacks, countless portals, disconnected records, repeated paperwork on clipboards and uncertainty surrounding next steps all shape how people perceive quality of care.

Communication once again sits at the center of the experience. Patients rarely separate operational snafus from expert care. They experience the entire journey as one connected reality – positive or negative.

The lesson is not that health care should behave exactly like retail commerce. Medicine carries ethical, scientific and regulatory responsibilities far beyond consumer transactions. Nevertheless, the operational expectations consumers now bring into the setting have changed.

People increasingly expect health care to be as responsive as the communication they experience elsewhere in life. Is that expectation reasonable?

The pharmaceutical industry, payers, providers, and health technology innovators must recognize that they no longer own just the patents on therapies, platforms or services. They also own the surrounding user experience.

Patients experience health as a continuous journey, not a “build your own adventure” exercise in navigating fragmented systems. Most people enter the system anxious and seeking reassurance from their health professionals. A delayed approval, clinically sterile information delivered through a diagnostic portal or a physician struggling to navigate complexity alongside them deepens that burden. These experiences shape how health care is remembered more powerfully than advertising campaigns or corporate positioning statements.

Those experiences ultimately shape reputations.

The future winners in health care will not simply develop innovative products. They will reduce friction around the human experience surrounding those products. They will recognize that communication, workflow design and responsiveness are not secondary considerations attached to innovation. They are part of the experience.

Patients and physicians rarely remember the elegance of molecular or system architecture behind a therapy or platform. They remember whether the experience made care delivery easier and more humane during moments that mattered.

The post Health Innovation Has a Friction Problem appeared first on Medika Life.

I have spent more than 30 years in healthcare with one consistent mission: helping people sustain and improve their lives. That mission has guided my work across large pharmaceutical companies, entrepreneurial startups, and academic institutions. It has shaped how I view innovation—not as a luxury, but as a necessity.

We often speak about healthcare innovation as if it exists in a vacuum. It does not. Innovation only matters if patients can access it, understand it, and afford it. Today’s system too often breaks that chain.

The U.S. healthcare system has evolved to prioritize risk management over prevention, short-term cost containment over long-term health, and utilization controls over patient outcomes. The consequences are real. Breakthrough therapies are delayed or denied. Preventive medicines are underused. Patients are left navigating complexity at the very moment they are most vulnerable.

However, innovation has repeatedly proven it can change the trajectory of disease—and lives—when it reaches patients.

Earlier in my career, I had the opportunity to help build Claritin into a household name. What made Claritin transformational was not just the molecule, but access. Non-sedating allergy relief allowed people to function—to work, learn, drive, and live daily life without compromise. We paired scientific innovation with brand-building, education, and emerging digital tools to enable patients to engage with their care in new ways. That experience taught me something enduring: innovation fails when it remains trapped behind complexity.

As digital channels emerged, I saw how virtual access could democratize care. Early online refill capabilities and digital front doors were not about marketing. They were about meeting patients where they were. Innovation is not only what happens in the lab; it is how solutions are delivered in the real world.

More recently, my work in cardiovascular and preventive medicine has reinforced this belief. Cardiovascular disease remains the leading cause of death globally, yet preventive innovation often struggles most to gain access. When therapies reduce future heart attacks, strokes, and hospitalizations—but do not show immediate cost offsets within narrow budget windows—they face resistance. This is actuarial logic colliding with human biology.

But prevention works. Inflammation matters. Long-term risk reduction matters. Helping people avoid catastrophic events enables them to remain productive, engaged, and present in their lives and with their families. The value of that outcome is difficult to capture on a quarterly balance sheet, but it is undeniable.

Innovation also matters because healthcare is not static. Populations are aging. Chronic disease is rising. Demand for care will only increase. Without continued pharmaceutical innovation—new mechanisms, better tolerability, improved adherence—we risk managing decline rather than enabling vitality.

Critics often frame innovation and affordability as opposing forces. They are not. The real tension lies between short-term system incentives and long-term societal benefit. When access to effective therapies is delayed or denied, costs do not disappear. They shift—reappearing as hospitalizations, disability, lost productivity, and diminished quality of life.

I have worked inside large organizations, small startups, and everything in between. I have seen how difficult it is to bring a medicine from concept to patient—and how fragile that final step of access can be. That is why innovation must be paired with thoughtful policy, modernized reimbursement, and a patient-centered view of value.

Healthcare should not be about simply surviving longer. It should be about living better for longer. Medical innovation, particularly in pharmaceuticals, plays a central role in making that possible. Even in a system burdened by complexity and constraints, innovation remains one of our strongest tools for advancing healthcare.

After three decades, my belief has not changed: when science, access, and mission align, lives improve. That is worth fighting to achieve.

The post Medical Innovation Still Matters—Even When the System Makes It Hard appeared first on Medika Life.

Lydia Romero strained to hear her husband’s feeble voice through the phone.

A week earlier, immigration agents had grabbed Julio César Peña from his front yard in Glendale, California. Now, he was in a hospital after suffering a ministroke. He was shackled to the bed by his hand and foot, he told Romero, and agents were in the room, listening to the call. He was scared he would die and wanted his wife there.

“What hospital are you at?” Romero asked.

“I can’t tell you,” he replied.

Viridiana Chabolla, Peña’s attorney, couldn’t get an answer to that question, either. Peña’s deportation officer and the medical contractor at the Adelanto ICE Processing Center refused to tell her. Exasperated, she tried calling a nearby hospital, Providence St. Mary Medical Center.

“They said even if they had a person in ICE custody under their care, they wouldn’t be able to confirm whether he’s there or not, that only ICE can give me the information,” Chabolla said. The hospital confirmed this policy to KFF Health News.

Family members and attorneys for patients hospitalized after being detained by federal immigration officials said they are facing extreme difficulty trying to locate patients, get information about their well-being, and provide them emotional and legal support. They say many hospitals refuse to provide information or allow contact with these patients. Instead, hospitals allow immigration officers to call the shots on how much — if any — contact is allowed, which can deprive patients of their constitutional right to seek legal advice and leave them vulnerable to abuse, attorneys said.

Hospitals say they are trying to protect the safety and privacy of patients, staff, and law enforcement officials, even while hospital employees in Los Angeles, Minneapolis, and Portland, Ore., cities where Immigration and Customs Enforcement has conducted immigration raids, say it’s made their jobs difficult. Hospitals have used what are sometimes called blackout procedures, which can include registering a patient under a pseudonym, removing their name from the hospital directory, or prohibiting staff from even confirming that a patient is in the hospital.

“We’ve heard incidences of this blackout process being used at multiple hospitals across the state, and it’s very concerning,” said Shiu-Ming Cheer, the deputy director of immigrant and racial justice at the California Immigrant Policy Center, an advocacy group.

Some Democratic-led states, including California, Colorado, and Maryland, have enacted legislation that seeks to protect patients from immigration enforcement in hospitals. However, those policies do not address protections for people already in ICE custody.

More Detainees Hospitalized

Peña is among more than 350,000 people arrested by federal immigration authorities since President Donald Trump returned to the White House. As arrests and detentions have climbed, so too have reports of people taken to hospitals by immigration agents because of illness or injury — due to preexisting conditions or problems stemming from their arrest or detention.

ICE has faced criticism for using aggressive and deadly tactics, as well as for reports of mistreatment and inadequate medical care at its facilities. Sen. Adam Schiff (D-Calif.) told reporters at a Jan. 20 news conference outside a detention center he visited in California City that he spoke to a diabetic woman held there who had not received treatment in two months.

While there are no publicly available statistics on the number of people sick or injured in ICE detention, the agency’s news releases point to 32 people who died in immigration custody in 2025. Six more have died this year.

The Department of Homeland Security, which oversees ICE, did not respond to a request for information about its policies or Peña’s case.

According to ICE’s guidelines, people in custody should be given access to a telephone, visits from family and friends, and private consultation with legal counsel. The agency can make administrative decisions, including about visitation, when a patient is in the hospital, but should defer to hospital policies on contacting next of kin when a patient is seriously ill, the guidelines state.

Asked in detail about hospital practices related to patients in immigration custody and whether there are best practices that hospitals should follow, Ben Teicher, a spokesperson for the American Hospital Association, declined to comment.

David Simon, a spokesperson for the California Hospital Association, said that “there are times when hospitals will — at the request of law enforcement — maintain confidentiality of patients’ names and other identifying characteristics.”

Although policies vary, members of the public can typically call a hospital and ask for a patient by name to find out whether they’re there, and often be transferred to the patient’s room, said William Weber, an emergency physician in Minneapolis and medical director for the Medical Justice Alliance, which advocates for the medical needs of people in law enforcement custody. Family members and others authorized by the patient can visit. And medical staff routinely call relatives to let them know a loved one is in the hospital, or to ask for information that could help with their care.

But when a patient is in law enforcement custody, hospitals frequently agree to restrict this kind of information sharing and access, Weber said. The rationale is that these measures prevent unauthorized outsiders from threatening the patient or law enforcement personnel, given that hospitals lack the security infrastructure of a prison or detention center. High-profile patients such as celebrities sometimes also request this type of protection.

Several attorneys and health care providers questioned the need for such restrictions. Immigration detention is civil, not criminal, detention. The Trump administration says it’s focused on arresting and deporting criminals, yet most of those arrested have no criminal conviction, according to data compiled by the Transactional Records Access Clearinghouse and several news outlets.

Taken Outside His Home

According to Peña’s wife, Romero, he has no criminal record. Peña came to the United States from Mexico in sixth grade and has an adult son in the U.S. military. The 43-year-old has terminal kidney disease and survived a heart attack in November. He has trouble walking and is partially blind, his wife said. He was detained Dec. 8 while resting outside after coming home from dialysis treatment.

Initially, Romero was able to find her husband through the ICE Online Detainee Locator System. She visited him at a temporary holding facility in downtown Los Angeles, bringing him his medicines and a sweater. She then saw he’d been moved to the Adelanto detention center. But the locator did not show where he was after he was hospitalized.

When she and other relatives drove to the detention facility to find him, they were turned away, she said. Romero received occasional calls from her husband in the hospital but said they were less than 10 minutes long and took place under ICE surveillance. She wanted to know where he was so she could be at the hospital to hold his hand, make sure he was well cared for, and encourage him to stay strong, she said.

Shackling him and preventing him from seeing his family was unfair and unnecessary, she said.

“He’s weak,” Romero said. “It’s not like he’s going to run away.”

ICE guidelines say contact and visits from family and friends should be allowed “within security and operational constraints.” Detainees have a constitutional right to speak confidentially with an attorney. Weber said immigration authorities should tell attorneys where their clients are and allow them to talk in person or use an unmonitored phone line.

Hospitals, though, fall into a gray area on enforcing these rights, since they are primarily focused on treating medical needs, Weber said. Still, he added, hospitals should ensure their policies align with the law.

Family Denied Access

Numerous immigration attorneys have spent weeks trying to locate clients detained by ICE, with their efforts sometimes thwarted by hospitals.

Nicolas Thompson-Lleras, a Los Angeles attorney who counsels immigrants facing deportation, said two of his clients were registered under aliases at different hospitals in Los Angeles County last year. Initially, the hospitals denied the clients were there and refused to let Thompson-Lleras meet with them, he said. Family members were also denied access, he said.

One of his clients was Bayron Rovidio Marin, a car wash worker injured during a raid in August. Immigration agents surveilled him for over a month at Harbor-UCLA Medical Center, a county-run facility, without charging him.

In November, the Los Angeles County Board of Supervisors voted to curb the use of blackout policies for patients under civil immigration custody at county-run hospitals. In a statement, Arun Patel, the chief patient safety and clinical risk management officer for the Los Angeles County Department of Health Services, said the policies are designed to reduce safety risks for patients, doctors, nurses, and custody officers.

“In some situations, there may be concerns about threats to the patient, attempts to interfere with medical care, unauthorized visitors, or the introduction of contraband,” Patel said. “Our goal is not to restrict care but to allow care to happen safely and without disruption.”

Leaving Patients Vulnerable

Thompson-Lleras said he’s concerned that hospitals are cooperating with federal immigration authorities at the expense of patients and their families and leaving patients vulnerable to abuse.

“It allows people to be treated suboptimally,” Thompson-Lleras said. “It allows people to be treated on abbreviated timelines, without supervision, without family intervention or advocacy. These people are alone, disoriented, being interrogated, at least in Bayron’s case, under pain and influence of medication.”

Such incidents are alarming to hospital workers. In Los Angeles, two health care professionals who asked not to be identified by KFF Health News, out of concern for their livelihoods, said that ICE and hospital administrators, at public and private hospitals, frequently block staff from contacting family members for people in custody, even to find out about their health conditions or what medications they’re on. That violates medical ethics, they said.

Blackout procedures are another concern.

“They help facilitate, whether intentionally or not, the disappearance of patients,” said one worker, a physician for the county’s Department of Health Services and part of a coalition of concerned health workers from across the region.

At Legacy Emanuel Medical Center in Portland, nurses publicly expressed outrage over what they saw as hospital cooperation with ICE and the flouting of patient rights. Legacy Health has sent a cease and desist letter to the nurses’ union, accusing it of making “false or misleading statements.”

“I was really disgusted,” said Blaire Glennon, a nurse who quit her job at the hospital in December. She said numerous patients were brought to the hospital by ICE with serious injuries they sustained while being detained. “I felt like Legacy was doing massive human rights violations.”

Handcuffed While Unconscious

Two days before Christmas, Chabolla, Peña’s attorney, received a call from ICE with the answer she and Romero had been waiting for. Peña was at Victor Valley Global Medical Center, about 10 miles from Adelanto, and about to be released.

Excited, Romero and her family made the two-hour-plus drive from Glendale to the hospital to take him home.

When they got there, they found Peña intubated and unconscious, his arm and leg still handcuffed to the hospital bed. He’d had a severe seizure on Dec. 20, but no one had told his family or legal team, his attorney said.

Tim Lineberger, a spokesperson for Victor Valley Global Medical Center’s parent company, KPC Health, said he could not comment on specific patient cases, because of privacy protections. He said the hospital’s policies on patient information disclosure comply with state and federal law.

Peña was finally cleared to go home on Jan. 5. No court date has been set, and his family is filing a petition to adjust his legal status based on his son’s military service. For now, he still faces deportation proceedings.

The post ‘I Can’t Tell You’: Attorneys, Relatives Struggle To Find Hospitalized ICE Detainees appeared first on Medika Life.

Last winter, Amber Wingler started getting a series of increasingly urgent messages from the local hospital in Columbia, Missouri, letting her know her family’s health care might soon be upended.

MU Health Care, where most of her family’s doctors work, was mired in a contract dispute with Wingler’s health insurer, Anthem. The existing contract was set to expire.

Then, on March 31, Wingler received an email alerting her that the next day Anthem was dropping the hospital from its network. It left her reeling.

“I know that they go through contract negotiations all the time … but it just seemed like bureaucracy that wasn’t going to affect us. I’d never been pushed out-of-network like that before,” she said.  

The timing was awful.

The query: When a Missouri mom’s health insurance company couldn’t come to an agreement with her hospital, most of her doctors were suddenly out-of-network. She wondered how she would get her kids’ care covered or find new doctors. “For a family of five, … where do we even start?”

— Amber Wingler, 42, in Columbia, Missouri

Wingler’s 8-year-old daughter, Cora, had been having unexplained troubles with her gut. Waitlists to see various pediatric specialists to get a diagnosis, from gastroenterology to occupational therapy, were long — ranging from weeks to more than a year.

(In a statement, MU Health Care spokesperson Eric Maze said the health system works to make sure children with the most urgent needs are seen as quickly as possible.)

Suddenly, the specialist visits for Cora were out-of-network. At a few hundred bucks a piece, the out-of-pocket cost would have added up fast. The only other in-network pediatric specialists Wingler found were in St. Louis and Kansas City, both more than 120 miles away.

So Wingler delayed her daughter’s appointments for months while she tried to figure out what to do.

Nationwide, contract disputes are common, with more than 650 hospitals having public spats with an insurer since 2021. They could become even more common as hospitals brace for about $1 trillion in cuts to federal health care spending prescribed by President Donald Trump’s signature legislation signed into law in July.

Patients caught in a contract dispute have few good options. “There’s that old African proverb: that when two elephants fight, the grass gets trampled. And unfortunately, in these situations, oftentimes patients are grass,” said Caitlin Donovan, a senior director at the Patient Advocate Foundation, a nonprofit that helps people who are having trouble accessing health care.

If you’re feeling trampled by a contract dispute between a hospital and your insurer, here is what you need to know to protect yourself financially:

1. “Out-of-network” means you’ll likely pay more.

Insurance companies negotiate contracts with hospitals and other medical providers to set the rates they will pay for various services. When they reach an agreement, the hospital and most of the providers who work there become part of the insurance company’s network.

Most patients prefer to see providers who are “in-network” because their insurance picks up some, most, or even all of the bill, which could be hundreds or thousands of dollars. If you see an out-of-network provider, you could be on the hook for the whole tab.

If you decide to stick with your familiar doctors even though they’re out-of-network, consider asking about getting a cash discount and about the hospital’s financial assistance program.

2. Rifts between hospitals and insurers often get repaired.

When Brown University health policy researcher Jason Buxbaum examined 3,714 nonfederal hospitals across the U.S., he said, he found that about 18% of them had a public dispute with an insurance company sometime from June 2021 to May 2025.

About half of those hospitals ultimately dropped out of the insurance company’s network, according to Buxbaum’s preliminary data. But most of those breakups ultimately get resolved within a month or two, he added. So your doctors very well could end up back in the network, even after a split.

3. You might qualify for an exception to keep costs lower.

Certain patients with serious or complex conditions might qualify for an extension of in-network coverage, called continuity of care. You can apply for that extension by contacting your insurer, but the process may prove lengthy. Some hospitals have set up resources to help patients apply for that extension.

Wingler ran that gantlet for her daughter, spending hours on the phone, filling out forms, and sending faxes. But she said she didn’t have the time or energy to do that for everyone in her family.

“My son was going through physical therapy,” she said. “But I’m sorry, dude, like, just do your exercises that you already have. I’m not fighting to get you coverage too, when I’m already fighting for your sister.”

Also worth noting, if you’re dealing with a medical emergency: For most emergency services, hospitals can’t charge patients more than their in-network rates.

4. Switching your insurance carrier may need to wait.

You might be thinking of switching to an insurer that covers your preferred doctors. But be aware: Many people who choose their insurance plans during an annual open enrollment period are locked into their plan for a year. Insurance contracts with hospitals are not necessarily on the same timeline as your “plan year.”

Certain life events, such as getting married, having a baby, or losing a job, can qualify you to change insurance outside of your annual open enrollment period, but your doctors’ dropping out of an insurance network is not a qualifying life event.

5. Doctor-shopping can be time-consuming.

If the split between your insurance company and hospital looks permanent, you might consider finding a new slate of doctors and other providers who are in-network with your plan. Where to start? Your insurance plan likely has an online tool to search for in-network providers near you. 

But know that making a switch could mean waiting to establish yourself as a patient with a new doctor and, in some cases, traveling a fair distance.

6. It’s worth holding on to your receipts.

Even if your insurance and hospital don’t strike a deal before their contract expires, there’s a decent chance they will still make a new agreement.

Some patients decide to put off appointments while they wait. Others keep their appointments and pay out-of-pocket. Hold on to your receipts if you do. When insurers and hospitals make up, the deals often are backdated, so the appointments you paid for out-of-pocket could be covered after all.

End of an Ordeal

Three months after the contract between Wingler’s insurance company and the hospital lapsed, the sides announced they had reached a new agreement. Wingler joined the throng of patients scheduling appointments they’d delayed during the ordeal.

In a statement, Jim Turner, a spokesperson for Anthem’s parent company, Elevance Health, wrote, “We approach negotiations with a focus on fairness, transparency, and respect for everyone impacted.”

Maze from MU Health Care said: “We understand how important timely access to pediatric specialty care is for families, and we’re truly sorry for the frustration some parents have experienced scheduling appointments following the resolution of our Anthem contract negotiations.”

Wingler was happy her family could see their providers again, but her relief was tempered by a resolve not to be caught in the same position again.

“I think we will be a little more studious when open enrollment comes around,” Wingler said. “We’d never really bothered to look at our out-of-pocket coverage before because we didn’t need it.”

Author: Bram Sable-Smith: brams@kff.org, @besables

Illustrations: Oona Zenda: ozenda@kff.org

The post So Your Insurance Dropped Your Doctor. Now What? appeared first on Medika Life.

CNS Summit: A Community, Not a Conference

The CNS Summit is less an event and more a movement, the roughly 900-person ecosystem of leaders, scientists, entrepreneurs, and communicators is bound by purpose. Through the years, it has become an “industry reunion” for those working at the intersection of science and humanity. Attendees don’t simply show up for “unscripted” presentations or networking; they come to commune, share ideas, listen and support each other’s journey.

Founded and carefully curated by Amir Kalali, MD, a former Quintiles executive, who focuses on the intersection of life science and technology, believes collaboration unleashes humanity’s greatest potential, Summit operates on the belief that innovation in clinical research and drug development depends on curiosity and connection.  Summit cultivates an atmosphere where hierarchy dissolves. CEOs engage with early-career professionals. Startups find champions among seasoned executives. Conversations flow freely, often long after formal sessions end. As the website declares, “The Summit brings together a curated group of top decision makers from pharma, biotech, CROs, investigator sites, patient advocacy groups, investors and other stakeholders.”

The site also notes a key differentiator for the 2025 gathering: “Networking tables throughout the day. A dedicated space for connection and conversation throughout Summit.” The Summit agenda reinforces that the gathering isn’t just about sessions; it’s about forging connections.

This is the kind of conference where attendees return year after year, sometimes at personal expense, because they recognize that the ROI is more than professional – it’s personal. You leave Boston with new insights, renewed energy and, often, lifelong friends.  What makes CNS Summit unique is that the “price of admission” includes year-long networking gatherings sponsored by Summit community leaders.

“When people introduce themselves at Summit, I want to hear about them — their backstory motivation first, and only then about the problem they are looking to solve,” shares long-time Summit attendee Craig Lipset, DTRA.org Co-Chair, and an advisor to global health innovation enterprises. “This is an event that cherishes long-term relationships between people, which is why this space has become so critical during such a volatile time in the industry,” he adds.

Communication Tip: At CNS Summit, authenticity amplifies influence. Don’t arrive with a set corporate pitch; come ready to share experiences and learn from others. This is a platform for vulnerability, curiosity and conversation, not self-promotion. In a community built on trust, the most powerful communication skill is listening.

The JP Morgan Healthcare Conference: The Ecosystem’s Main Stage

If the CNS Summit is a retreat for reflection, the JP Morgan Healthcare Conference is the watering hole of the life science world, crowded, noisy and absolutely vital. JP Morgan frames it as the “largest and most informative healthcare investment symposium in the industry, which connects global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. For one week in January, from January 12^th to 15^th 2026, the health innovation universe converges in San Francisco.

In contrast to the CNS Summit’s intimacy, JPMorgan thrives on scale. It is where biotech, pharma and health system hopefuls present their value proposition to investors, and where global biopharma companies reaffirm strategic direction. From hotel lobbies to sidewalk cafés, every table and hallway becomes a “pitch” space. Deals are initiated, relationships rekindled, and reputations built, rebuilt or crushed. Mega consulting groups such as McKinsey emphasize that this gathering unites “global health and life sciences industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.”

You might attend JPMorgan for 72 hours and never set foot in an official session. Yet those unscripted encounters, coffee chats, quick handshakes, five-minute updates, often shape company trajectories and careers alike for the coming year.

Fern Lazar, Managing Partner and Global Health Practice Lead at FINN Partners, has attended the J.P. Morgan Healthcare Conference since its early days as the original Hambrecht & Quist Healthcare Conference—later acquired by J.P. Morgan. Her advice is straightforward: “Preparation is power. The companies that arrive with clarity, confidence, and proof of momentum leave with stronger reputations, investor trust, and new alliances. Those that don’t are quickly forgotten.”

Communication Tip: At JPMorgan, clarity is currency. In a sea of sound bites, those who communicate with precision rise above the noise. Be concise, compelling, and credible. Articulate what your company does, and why it matters to patients, to systems, and to investors. Every sentence should connect back to the vision and value with plenty of proof points to show you’re on the right track.

Why Both Matter to the Future of Health

Both conferences reveal something fundamental about the health industry’s DNA: innovation depends on both connection and coopetition. CNS Summit reminds us that science is human, built on relationships of trust. JP Morgan reminds us that sustainability requires strategy, clarity and capital.

For communication leaders, the lesson is clear: health innovation demands head, heart and gut.  You must speak to investors in the language of returns and to peers and partners in the language of purpose. The best communicators, like the best leaders, bridge both worlds seamlessly.

The life sciences sector is undergoing constant ebbs and flows: AI, digital biomarkers, decentralized trials and real-world data are reshaping how therapies are discovered, developed and delivered amid this race to raise the bar on all aspects of health access, affordability and delivery, leadership visibility and stakeholder trust matter more than ever.

At the CNS Summit, you cultivate the credibility that comes from empathy and engagement. The Summit community underscores that year-round social element: “Your event registration also provides access to our year-round programming and community activities.”  At JP Morgan, you demonstrate the confidence and messaging that attracts capital and partnership.

One builds influence, the other builds momentum. Taken together, they form a powerful narrative arc for any organization serious about advancing science and health innovation. The leaders who succeed in the next decade won’t just be the ones with great science, they will be those who can translate that science into stories that move payers, policymakers and patients alike. It’s the combination of IQ and EQ that will rally companies toward success.

Final Words: Show Up, Listen, Learn and Lead

Conferences are catalysts for connection.  Their value lies in what happens after the panels end and the flights home begin. Do you follow up? Do you stay in touch? Do you turn introductions into impact?

Whether you’re heading to Boston or San Francisco or both remember: your presence is an investment in the future of your career, company and community. Be intentional. Be visible. Most importantly, be human. In this ecosystem of change, as in medicine itself, the most significant advances begin when people listen, learn and lead together.

The post Two Gatherings, One Mission: Elevating Life Science Leadership and Communication appeared first on Medika Life.

Department of Health and Human Services Secretary Robert F. Kennedy Jr. has floated a seismic idea: adding autism to the list of conditions covered by the Vaccine Injury Compensation Program. The program, known as VICP, provides a system for families to file claims against vaccine providers in cases in which they experience severe side effects. Kennedy has also suggested broadening the definitions of two serious brain conditions — encephalopathy and encephalitis — so that autism cases could qualify.

Either move, experts warn, would unleash a flood of claims, threatening the program’s financial stability and handing vaccine opponents a powerful new talking point.

Legally, HHS “is required to undergo notice and comment rulemaking to revise the table,” said Richard Hughes, a law firm partner who teaches at George Washington University. The “table” is a list of specific injuries that the U.S. government accepts as presumed to be caused by a vaccine if those injuries occur within a certain time window. If someone can show they meet the criteria, they have a simpler path to securing compensation without having to prove fault. Autism is not in the table because a link between vaccines and autism has been thoroughly debunked.

If autism is added, Hughes explained, the VICP could face “an exorbitant number of claims that would threaten the viability of the program.”

Asked about its possible plans, an HHS spokesperson told CBS News the agency does not comment on future or potential policy decisions.

Carole Johnson, former administrator of the Health Resources and Services Administration, which oversees VICP, cautioned that the system is already overburdened: “The backlog is not just a function of management, it’s built into the statute itself. That’s important context for any conversation about adding new categories of claims.”

Dorit Reiss, a law professor at the University of California College of the Law-San Francisco, said that any such change would be exploited: “This can, and likely will, be used to cast doubt on vaccines.”

Compensation Without Causation

The Vaccine Injury Compensation Program was born of crisis. In 1982, “Vaccine Roulette,” a television documentary, aired nationwide, alleging routine childhood shots were causing seizures, brain damage, and even sudden infant death. The program alarmed parents and triggered a surge of lawsuits against vaccine makers.

“That led to a flood of litigation against vaccine makers,” recalled Paul Offit, a pediatric infectious disease specialist and vaccine inventor at the University of Pennsylvania. “I mean, to the point that it drove them out of the business. … By the mid-1980s, there were $3.2 billion worth of lawsuits against these companies.”

Were it not for the VICP, Offit said, “We wouldn’t have vaccines for American children. The companies — it wasn’t worth it for them.”

The National Childhood Vaccine Injury Act of 1986 created a no-fault system. Families who believed a vaccine caused harm could file a claim; if the injury appeared on the table within a set time frame, compensation was automatic. If not, claimants could present medical evidence. The system had two purposes: provide compensation and protect the vaccine supply.

From the beginning, the table was understood not as a scientific document but as a legal tool.

“It’s a legal document and things can be included for policy reasons even if the causation evidence is weak,” Reiss said. She explained, “The program is designed to be generous, to compensate in cases of doubt.”

But, she said, “autism is not in that category. The science is clear. Adding it would be pure politics.”

This tension — between law, science, and public perception — has defined the program for nearly four decades.

What Expansion Would Mean in Practice

Since 1988, federal data shows more than 25,000 petitions to the VICP have been adjudicated; of those, 12,019 were granted compensation and 13,007 were dismissed. About 60% of compensated cases involved negotiated settlements in which HHS drew no conclusion about the cause. Over the same period, billions of vaccine doses were safely administered to millions of Americans.

Adding autism to the VICP table would change that picture overnight.

Federal estimates suggest up to 48,000 children could qualify immediately under a “profound autism” standard, with potential payouts averaging $2 million per case, at an initial cost of nearly $100 billion, followed by annual totals of about $30 billion a year — dwarfing the current $4 billion trust, a new analysis finds.

“Any case where the symptoms appeared in the past eight years and the parents blame vaccines,” Reiss said. “I don’t know how many that would be. The fund has a surplus of over $4 billion. One seriously disabled child’s care can cost millions, so a significant number, say 100,000 compensations, might exhaust it.”

Furthermore, with only eight special masters handling cases, the system would also be paralyzed by backlogs.

The stakes are not just fiscal. If the fund collapses under the weight of autism claims, vaccine makers may question whether producing vaccines for the U.S. market is worth the risk. That would mirror the crisis of the 1980s, which led to the establishment of the VICP.

Autism and the Courts

In the late 1990s and early 2000s, Andrew Wakefield’s now-retracted paper alleging a link between the MMR vaccine and autism fueled a surge of VICP claims. By 2002, the VICP was swamped with petitions alleging vaccines had caused autism. The court consolidated thousands of cases into the Omnibus Autism Proceedings, selecting a handful of test cases to decide them all.

After years of hearings and expert testimony, the conclusion was unequivocal: vaccines do not cause autism. In 2010, the court ruled against petitioners on every theory of causation. The U.S. Court of Federal Claims affirmed, and the Court of Appeals upheld, the decision.

“That precedent is binding,” said Richard Hughes, a vaccine law expert at George Washington University and former VICP legal counsel. “Autism was litigated thoroughly and rejected. That still carries weight in the court today.”

The Ghost of Hannah Poling

Yet, the vaccine-autism debate has never quite faded. In 2008, the government conceded a case involving Hannah Poling, a girl with a rare mitochondrial disorder who developed autism-like symptoms after vaccination. Officials stressed the concession was specific to her condition, not evidence of a general link. But headlines told another story: “Family to Receive $1.5 Million in First-Ever Vaccine Autism Court Award.”

The Poling case fueled years of confusion.

Autism Science Today

The science is clearer than ever. Autism begins early in pregnancy, not in toddlerhood when most vaccines are given.

“Vaccinations … happened around the time families were recognizing symptoms of autism in their children,” said Catherine Lord, a UCLA clinical psychologist and specialist in autism diagnosis. “However, we now know that autism begins much earlier, likely as the fetus develops during pregnancy, so it cannot be an explanation.”

Peter Hotez, a pediatric infectious disease specialist and vaccine scientist at the Baylor College of Medicine who is also the father of a young adult with autism, underscores that point: “The drivers of autism are genetics and, in rare cases, environmental exposures during pregnancy, not vaccines. We’ve been over this ground for decades, and the evidence is overwhelming.”

Sarah Despres, former legal counsel to the secretary of Health and Human Services in the Biden administration and now a consultant to nonprofit organizations on immunization policy, adds that the compensation program itself is often misunderstood.

“The table was originally written as a political document,” she said. “The purpose of the program was to be swift, generous, and fair. … There would be cases that may not be caused by the vaccine but would be compensated if you went through this table injury scheme, where you don’t have to prove causation.”

What’s at risk: Harm from the Diseases Themselves

The stakes are not abstract. Measles, one of the most contagious pathogens on Earth, spreads so efficiently that one infected child can transmit it to 90% of susceptible contacts. Before vaccinations began in the 1960s, measles sickened hundreds of thousands annually in the U.S., killing hundreds and causing thousands of cases of encephalitis and lifelong disability. Complications included pneumonia, brain swelling, and, in rare cases, a fatal degenerative brain disorder called subacute sclerosing panencephalitis, or SSPE, that can strike years later. This year, a school-age child in Los Angeles County died of SSPE after contracting measles in infancy, before being eligible for vaccination.

Mumps was once a near-universal childhood illness. Though often dismissed as mild, it can cause sterility in men, meningitis, and permanent hearing loss. Outbreaks on college campuses, as recently as the 2000s, showed how quickly it can return when vaccination rates slip.

Rubella, also known as German measles, is mild in most children, but can be devastating during pregnancy. Congenital Rubella Syndrome, or CRS, caused waves of tragedy before the development of the vaccine: Thousands of babies each year were born blind, deaf, with heart defects, or with intellectual disabilities. In medical texts, autism itself is listed as one of CRS’ sequelae, or possible consequences — proof that rubella infection, not vaccination, can contribute to developmental disorders.

Measles, mumps, and rubella “are not trivial,” said Walt Orenstein, former head of the Centers for Disease Control and Prevention’s immunization program. “Fever, high fever, is common … and they have frequent complications.”

And yet, as these diseases fade from living memory, a counternarrative has gained traction. On Sept. 29, the nonprofit Physicians for Informed Consent, a group that disputes the scientific consensus on vaccines, announced it had mailed its “Silver Booklet” on vaccine safety to every member of Congress, as well as to President Donald Trump and Vice President JD Vance. The book claims that “vaccines are not proven to be safer than the diseases they intend to prevent,” and calls on federal leaders to punish states that restrict vaccine exemptions. (The booklet isn’t free. The group sells copies for $25 on Amazon.)

Scientists say this framing misrepresents the basic math of risk. “Measles is one of the most important infectious diseases in human history,” notes “Plotkin’s Vaccines,” the field’s authoritative textbook. “The widespread use of measles vaccines in the late 20th and early 21st centuries led to a further marked reduction in measles deaths. Measles vaccination averted an estimated 31.7 million deaths from 2000 to 2020.”

Kennedy’s possible move to expand the Vaccine Injury Compensation Program hinges on casting doubt — on suggesting that science is unsettled, that vaccines may be riskier than diseases.

“One tactic used to argue that vaccines cause autism is the use of compensation decisions from the National Vaccine Injury Compensation Program to claim such a link,” said Reiss of UC Law-San Francisco. “Even the cases that most closely address the question of vaccines and autism do not show the link that opponents claim exists, and many of the cases used are misrepresented and misused.”

Offit underscores the danger on the perception side. “When people see the Vaccine Injury Compensation program, they assume that any money that is given is because there was a vaccine injury,” he said.

Kathryn Edwards, an expert in pediatric infectious diseases and vaccine safety at Vanderbilt University, said, “Expanding compensation for issues that are not clearly related to vaccines … suggests that these conditions are related to vaccines when they are not.” She compared it to the removal of thimerosal, a preservative dropped from most childhood vaccines to ease public fears, despite no evidence of harm. “Now, we are still suffering from that action.”

Public health experts stress that such narratives invert reality. The very diseases being downplayed once killed or disabled tens of thousands of American children each year. As pediatrician, psychiatrist, and medical historian Howard Markel put it: “Back a hundred years ago, everybody lost a kid or knew a kid who died of one of these diseases. … We never conquer germs, we wrestle them to a draw. That’s the best we do. And so this is a real … handicap to the other side, the microbes who live to infect.”

Families and the Future

The hardest voices to reckon with are those of families. Parents of autistic children often feel abandoned — unsupported by disability programs, exhausted by care needs, searching for answers. Kennedy’s appeal to them is emotional, not scientific.

Reiss noted that families deserve far more support but argues that it shouldn’t come through VICP.

“The program is to award compensation to those injured by vaccines,” she said. “We should have more direct support — disability funding, disability aid. Kennedy has been taking HHS in the opposite direction, cutting services where we need more.”

Despres made the same point: “The goal of the program really was if there’s a close call, we’re going to err on the side of compensation. … And it’s really important that everyone understands that compensation does not mean that the vaccine actually caused the injury. … And I think we have seen statistics around the compensation program misused by those who would want to sow distrust in vaccines, to say vaccines are unsafe, when in fact … that’s not what this is.”

UCLA’s Lord urged a shift in focus. “For the last 50 years, science has focused on the biological causes of autism, which has led to great progress, especially in genetics,” she said. Of Secretary Kennedy, she said, “He could help more by acknowledging the value of science, but also the need to better attend to the actual lives of autistic people and their families.”

What Comes Next?

If Kennedy decides to move forward with such a plan, HHS would need to draft a rule, open it to public comment, and then defend the change in court. The pushback will be fierce: from scientists, from public health leaders, and from families who fear being misled yet again.

The debate over adding autism to the Vaccine Injury Table is not just a policy debate. The program was built on the principle of compensation without causation, a fragile balance designed to sustain both trust and supply. Adding autism could collapse that distinction entirely.

[KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.]

The post Inside the High-Stakes Battle Over Vaccine Injury Compensation, Autism, and Public Trust appeared first on Medika Life.

We are a species enamored with technology. I count myself among the early adopters who eagerly embraced gadgets promising to reshape how we live and heal. I owned an Apple Newton decades before smartphones became second nature. I strapped on a Fitbit long before step-counting became a cultural norm. I’ve carried an AliveCor device to track my heart rhythm because I care about heart health.

I’m fascinated by AI and impressed by the capabilities of ChatGPT and other large language models. But through all of it, a pattern emerges: while we sprint forward with healthtech innovation, we often overlook the element that gives health its soul—human empathy.

Hollywood’s visions of the future play out that tension. Films like iRobot and Outside the Wire imagine a world where advanced technology surrounds humans. Yet even in these hyper-connected futures, the human spirit, judgment and emotional resonance triumph over computation. Tech may win the movie battle, but empathy wins humanity’s greatest challenges.

So, the question becomes: in our real love affair with technology, how do we ensure that it doesn’t diminish our humanity but enhances it?

Digital Health’s Expanding Horizon

Health delivery is at a crossroads. On one hand, we are real-time participants in a sea-changing Cambrian explosion of innovation—AI models reading radiology scans, wearable devices transmitting real-time health data from patient to provider, voice assistants aiding mental health, AI tools “scraping” data from EMRs and predictive algorithms alerting physicians to early signs of disease. On the other hand, the average patient still struggles to schedule an appointment, reach a care coordinator, navigate their health insurance coverage or feel heard during a clinical encounter.

Digital health evolves faster than we can emotionally and ethically integrate into the care journey. As Hal Wolf, CEO of global NGO HIMSS, said in a 2025 HIMSS Europe keynote, “Old Organization + New Technology = Expensive Old Organization.” The implication is clear: technology alone is not transformation. It is a tool that is only as effective as the system and the people who apply it with purpose.

The Role of Emotion in Healing

John Nosta, a leading innovation theorist and founder of NostaLab, explores health decisions’ emotional and cognitive complexity in his essay Unraveling the Human Mind. He highlights the importance of understanding emotions like joy, guilt, and envy in AI development, reminding us that behavior is not driven solely by data but by deeply human emotional processes. This insight is critical: health behaviors—whether quitting smoking, taking medication, or attending a follow-up appointment—are deeply influenced by fear, hope, anxiety, trust and love.

AI can surface patterns, but it cannot feel. It can summarize a patient’s medical history, but cannot detect the tremble in their voice when they say, “I’m scared.” We must not confuse intelligence with insight or information with understanding.

Empathy as a Design Principle

For health tech to reach its most significant potential, we must design systems that understand and adapt to the human condition. That means:

Unfortunately, many current implementations miss the mark. A chatbot that dismisses a patient’s concerns with canned responses doesn’t reflect innovation—it reflects embedded institutional indifference. An app that tracks glucose but fails to create bridges to a community of support doesn’t reflect progress—it reflects a missed opportunity for connection and adherence.

The Power of AI and LLMs

Tom Lawry, former National Director for AI in Health & Life Sciences at Microsoft, captures this idea succinctly: “AI can automate highly repetitive activities and augment activities that are more highly varied and require a higher level of problem solving.” This duality reflects the essence of digital health transformation—technology that supports human expertise, not replaces it.

When used with intention, large language models like ChatGPT can democratize information, translate medical jargon, and surface unseen risks. They are powerful co-pilots in care. But they lack the capacity for compassion and their accuracy rests solely with the people designing the system.

I’ve often said that communication is the currency of care. That truth remains. The best outcomes emerge not from algorithms alone but from conversations between doctors and patients, health systems and communities, policymakers and people. Technology can facilitate these conversations, but it cannot replace them.

Leadership Needed

This is a call to the architects of our health future: More than “Don’t forget the patient, the caregiver, or the person behind the data,” people must be at the center of the action. We must remember that we are always people, only sometimes patients. Therefore, we need leaders—inside industry, government, academia and advocacy—who understand that digital transformation must be human-centered.

At the intersection of health and technology, we need humility. We need to listen more, build thoughtfully and measure success not just by the speed of a process or precision of a model, but by the quality of life it helps sustain and save.

Reimagining the Health-Tech Love Story

Our fascination with technology isn’t wrong. It’s natural. Much like the cinematic heroes in iRobot and Outside the Wire, we are drawn to machines’ capabilities but are also reminded that their greatest strengths emerge when paired with human insight. In those stories, it is not the tech that ultimately saves the day but the human instinct for empathy, ethics and engagement.

Progress is essential. But as we reimagine the health ecosystem, we must write a new love story—one where technology and empathy are co-stars, not competitors. One where innovation is in service of intimacy, and the promise of AI is fulfilled not in clinical outputs, but in human outcomes.

As someone who has watched health tech innovation unfold through the decades—from Apple Newton to neural networks—I remain hopeful. But hope, like health, is a human trait. It can’t be programmed. It must be lived.

Let’s remember that healing is not just about fixing bodies. It’s about touching hearts. Let’s code for that.

The post Human First: Reclaiming Empathy in Our Love Affair with Health Tech appeared first on Medika Life.

The launch of Roferon-A, alpha interferon marked a watershed moment in medicine: the first biotherapeutic to treat cancer, targeting the rare disease hairy-cell leukemia. I remember the packed press conference at The Pierre Hotel in New York City. Thought leaders like Dr. Jerome Groopman inspired awe. Headlines followed. The world paid attention.

That was decades ago. Since then, the biotech sector has evolved from fragile start-up spirit into a multibillion-dollar force. In the eyes of many, what was once miraculous has become mundane. And yet, the science has only grown more awe-inspiring. So why don’t we talk about it that way anymore?

Have we become numb to the very progress that extends and saves lives?

Biotechnology is arguably one of humanity’s most transformative achievements. From precision cancer immunotherapies to gene editing tools like CRISPR, we’ve leapt across medical milestones that were once the stuff of science fiction. CAR-T cell therapy rewrites the body’s immune system; mRNA platforms taught us how to respond to pandemics in real time; and personalized medicine now tailors treatments to the uniqueness of our DNA.

Despite these triumphs, we now face a paradox: the more frequently we succeed, the less exceptional it seems. Biotech, in its reliability, risks becoming background noise.

The danger here isn’t just perception—political, economic, and moral. When we stop being amazed, we stop advocating. And advocacy is essential, because science doesn’t fund itself.

The Birth of a Movement: BIO’s Role in Advancing Innovation

In the early days of this field, the promise of biotech required more than scientific breakthroughs—it demanded an organized, united voice to advocate for science, policy, funding, and public trust. That’s when the Biotechnology (Industry) Innovation Organization (BIO) emerged, uniting a fledgling industry around a shared mission: to promote innovation and ensure that the fruits of biotech reach the people who need them most.

What began as a coalition of pioneers has evolved into one of the most influential global voices for biotechnology. BIO has helped shape legislation, fostered partnerships, supported startups, and advanced equity in access and clinical trials. It has been a tireless advocate for the idea that science serves people—and that innovation without access is innovation incomplete.

As we reflect on biotech’s journey—from niche science to essential public health engine—BIO’s efforts to engage policymakers, educate the public, and convene global stakeholders at events like the annual BIO International Convention, BIO2025 have played a defining role. It’s a reminder that scientific progress is never just about the petri dish. It’s about ecosystems—coalitions of scientists, communicators, investors, and institutions aligned toward a common good.

The Threat of Institutional Apathy

Innovation doesn’t flourish in a vacuum. It requires funding, partnerships, regulatory foresight, and yes, public interest. Today, with DOGE pinching national budgets and partisanship clouding consensus, Federal funding for research is under threat. The National Institutes of Health (NIH), the world’s largest public funder of biomedical research, faces increasingly skeptical eyes and plummeting appropriations.

In parallel, biotech investors—once exuberant—have become cautious. Valuations are down. IPO windows are narrow. Even promising start-ups are forced to downsize or shutter. This isn’t just an economic cycle. It’s a societal test.

If we stop investing in innovation, diseases that could have been conquered will remain entrenched. Rare conditions will stay rare because they’re unprofitable. And the promise of personalized, preventive care will fade back into abstraction. Let’s take stock.

We’ve made incredible strides in HIV, hepatitis C, certain leukemias, and now we see glimpses of progress in previously unyielding diseases like ALS and pancreatic cancer. In some cases, such as HIV, biologics have helped turn some diseases into manageable conditions. Patients who once faced death sentences now live long, productive lives.

But so much work remains. Alzheimer’s disease continues to challenge us. Autoimmune conditions like lupus and Crohn’s demand better solutions. Pediatric rare diseases—often overlooked—leave families desperate for options. And mental health, despite its growing visibility, remains underfunded and underexplored from a biotherapeutic standpoint.

We can’t stop now. The urgency is not over.

Science Needs Storytellers

One of the most potent forces in advancing biotherapeutics isn’t just the lab bench—it’s the lens through which the public sees that bench. This is where communicators come in.

Media, public relations professionals, and advocacy leaders are not passive observers. We are active players in this ecosystem. When we frame scientific progress as human progress, we drive interest, funding, and talent into the field. When we tell stories that connect molecules to people, we give science a face—and a heartbeat.

In the early days of Roferon-A, calls from a young PR pro would turn out a full-room press conference, launching a wave of national interest. Today, the media landscape is fragmented. Clicks compete with credibility, and sensationalism wins over substance.

That only means our responsibility has grown. We must elevate the authentic voices of scientists, patients and advocates. We must cover biotech stories not just as business news, but as human stories, because they convey the struggle and potential.

Bench to Bedside is a Human Endeavor

Behind every molecular breakthrough is a researcher who missed birthdays to run experiments, a trial participant who volunteered without knowing the outcome, and a caregiver hoping that science can offer one more chance. We cannot allow their efforts to be invisible.

Let us remember that biotherapeutics are not just lab products—they are the embodiment of human hope and courage. Each FDA approval to market is a victory for a company and a patient.

And yet, even as we acknowledge this, we must grapple with another complexity: equity.

Not all communities have equal access to these innovations. Biologics are expensive. Insurance structures are slow to adapt, sometimes even resisting. Global disparities persist. If we believe in the power of biotech, we must also commit to making it accessible, advocating for affordability, inclusive clinical trials and compassionate pricing strategies.

Reclaiming the Wonder

So, where do we go from here?

We start by reawakening awe. As communicators, we must use our platforms to remind the world that biotech is not just another industry—it is a movement, a mission.

We must protect the budgets that sustain research, defend the credibility of science against misinformation, and inspire young minds to enter STEM fields not just for jobs but for the opportunity to change lives.

It starts with how we talk. Let’s use language that evokes possibility. Let’s tell stories that illuminate the patient journey. Let’s spotlight scientists with the same reverence we show to athletes or entertainers.

Biotech Without Borders

The original promise of biotechnology was to break boundaries between disciplines, possibilities, and life and death. That promise is still alive, but it needs guardians.

Now more than ever, biotech needs communicators, policymakers, and citizens who care.

I remember the days when biotech press conferences made front pages. Maybe we’ll never go back to that exact moment. But we can choose to go forward—together—into a future where science is again seen not just as data, but as destiny.

Let’s reclaim the wonder. Let’s continue to give scientists a voice, patients hope, start-up enterprises resources, and policymakers direction.

Because what’s at stake is not just the next miracle drug.  What’s at stake is our collective belief that we can still do miraculous things.

The post Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age appeared first on Medika Life.

Usually, detecting cancer is done through a combination of physical exams, imaging tests, blood tests, and biopsies. A biopsy, where a tissue sample is taken and examined under a microscope. This process is time-consuming and often relies on parts of the health system working together quickly, which does not always happen. Some cancers, like brain, pancreatic, and ovarian cancers, are difficult to detect, which can slow diagnosis even further.

By contrast, liquid biopsies can detect cancer more quickly. This type of testing looks at bodily fluids (typically blood) for evidence of cancer cells by finding biomarkers that are shed by cancer cells into the bloodstream. Liquid biopsy technology is advancing fast and with new technologies emerging, such as using light to detect these signals. This is a similar approach to that used when small swabs are passed over luggage and analysed at airport security.

By combining this spectral analysis with artificial intelligence (AI), it is possible to speed up cancer detection at a significantly lower cost. At the forefront of this revolution in cancer detection is Dr. Holly J. Butler. Dr Butler is the co-founder and CTO of Dxcover, the company behind the award-winning multiomic spectral analysis platform. Grounded in biophotonics and driven by an unwavering dedication to improving patient outcomes, Dr Butler is striving to bring about a new era of non-invasive diagnostics; one where a couple of drops of blood and a beam of light might one day save millions of lives.

Dr Butler, alongside an award-winning leadership and research team, has been developing methods to analyse blood samples using infrared spectroscopy. What they discovered was a way of ‘reading’ the biochemical fingerprint of disease in a standard blood test. This research became the foundation of an award-winning proprietary platform that leverages a unique combination of AI and spectral analysis to detect patterns in small blood amounts, allowing clinicians to find cancer earlier, more accurately, and far more affordably than many existing techniques.

The potential is enormous. Unlike conventional liquid biopsies, which rely on picking up fragments of tumour DNA, this platform is more wide-ranging in its approach. It uses a multiomic strategy – looking at proteins, lipids, metabolites, and more – through a process known multiomic spectral analysis. It translates to even tiny tumours, sized at just 0.2 cm, being capable of leaving a detectable trace. And it’s all done with just nine microlitres of blood.

Dr Butler’s drive to transform scientific ideas into reality started early. After her Ph.D., she took on a Scottish Enterprise-funded project to translate laboratory-based research into clinical diagnostics. Her entrepreneurial endeavours were making waves as early as 2017 – she was ‘Young Entrepreneur of the Year’ at the Scottish Women’s Awards and received the Women in Innovation award at the Global Game Changers Awards. She has continued to be a vocal advocate for women in STEM and an active mentor to early-career scientists and entrepreneurs via the Strathclyde Inspire network in the intervening period.

“I’ve always been drawn to problems where science can make a real, tangible difference in people’s lives,” she says. “To me, early detection for the most difficult to detect cancers is one of the biggest, most urgent problems we face – and one we hope to solve.”

Dr. Butler’s role in bringing this innovation along is as much practical as it is strategic. She is part of a team that spans lab operations, data, software, quality and regulatory affairs, pushing the science to clear the bars for real-world medical use. “You can’t just invent a technology,” she says. “You need to prove that it works, scale it with safety, meet stringent quality specifications, and prove how it fits into clinical pathways. That is the challenge.”

For Dr Butler, it is about the impact on lives. “Cancer still kills nearly 10 million people a year,” she says. “The difference between early or late detection can be life and death. We want to make early detection routine – not something that’s just for some individuals or comes too late.”

Now pursuing an Executive MBA, Dr. Butler is expanding her leadership credentials. “Science gave me the means to innovate,” she says. “But the MBA is teaching me to lead, to strategise, to build something that can last.”

That ecosystem, she hopes, will be one where innovation and inclusion go hand-in-hand. She’s particularly passionate about ensuring that diagnostic breakthroughs become accessible across communities. “We’re aiming for a future where your GP can run a test like this early—long before you’re even referred to a specialist,” she explains.

Dr. Butler’s work remains patient-centred and personal. “Every time we detect a cancer that would have been missed – that’s the goal,” she says. “And every time we improve the technology is a step closer to a world where fewer people have to hear the words, ‘if only we’d caught it sooner.'”

The post Shining a Light on Early Cancer Detection appeared first on Medika Life.